1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET SNAPSHOT
3.2 GLOBAL CTC DIAGNOSTICS MARKET REVENUE, 2017 – 2025 (US$ BN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS, %, 2016
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY TECHNOLOGY
5.1 OVERVIEW
5.2 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) ENRICHMENT, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.3 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) DETECTION, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR CTC ANALYSIS; VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BREAST CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR LUNG CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR COLORECTAL CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PROSTATE CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.6 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR OTHERS (SKIN CANCER, PANCREATICCANCER & OVARIAN CANCER) CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY END-USER
7.1 OVERVIEW
7.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BIOTECHNOLOGICAL RESEARCH CENTERS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR , HOSPITALS & CLINICS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PHARMACEUTICALS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR, ACADEMIC RESEARCH INSTITUTIONS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
8 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 NORTH AMERICA
8.1.1 MARKET DYNAMICS
8.1.1.1 Drivers
8.1.1.2 Restraints
8.1.1.3 Opportunity
8.1.2 U.S.
8.1.3 CANADA
8.1.4 MEXICO
8.2 EUROPE
8.2.1 MARKET DYNAMICS
8.2.1.1 Drivers
8.2.1.2 Restraints
8.2.1.3 Opportunity
8.2.2 U.K.
8.2.3 ITALY
8.2.4 FRANCE
8.2.5 GERMANY
8.2.6 RUSSIA
8.2.7 SPAIN
8.2.8 REST OF EUROPE
8.3 ASIA PACIFIC
8.3.1 MARKET DYNAMICS
8.3.1.1 Drivers
8.3.1.2 Restraints
8.3.1.3 Opportunity
8.3.2 INDIA
8.3.3 CHINA
8.3.4 JAPAN
8.3.5 AUSTRALIA
8.3.6 REST OF ASIA PACIFIC
8.4 MIDDLE EAST AND AFRICA
8.4.1 MARKET DYNAMICS
8.4.1.1 Drivers
8.4.1.2 Restraints
8.4.1.3 Opportunity
8.4.2 GCC
8.4.3 SOUTH AFRICA
8.4.4 REST OF MIDDLE EAST AND AFRICA
8.5 LATIN AMERICA
8.5.1 MARKET DYNAMICS
8.5.1.1 Drivers
8.5.1.2 Restraints
8.5.1.3 Opportunity
8.5.2 BRAZIL
8.5.3 REST OF LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 NEW PRODUCT LAUNCHES
10 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 ADNAGEN AG
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 OUR COMPANY VIEW
10.3 ADVANCED CELL DIAGNOSTICS
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 OUR COMPANY VIEW
10.4 AVIVA BIOSCIENCES CORP.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 OUR COMPANY VIEW
10.5 BIOCEPT, INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 OUR COMPANY VIEW
10.6 CELULA, INC.
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 OUR COMPANY VIEW
10.7 CYNVENIO BIOSYSTEMS, INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 OUR COMPANY VIEW
10.8 EPIC SCIENCES, INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 OUR COMPANY VIEW
10.9 FLUXION BIOSCIENCES, INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 OUR COMPANY VIEW
10.10 MENARINI SILICON BIOSYSTEMS, INC.
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 OUR COMPANY VIEW
10.11 NANOSTRING TECHNOLOGIES, INC.
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS & SERVICES
10.11.3 KEY STRATEGY
10.11.4 RECENT DEVELOPMENTS
10.11.5 SWOT ANALYSIS
10.11.6 OUR COMPANY VIEW
10.12 RARECELLS, USA
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS & SERVICES
10.12.3 KEY STRATEGY
10.12.4 RECENT DEVELOPMENTS
10.12.5 SWOT ANALYSIS
10.12.6 OUR COMPANY VIEW
10.13 VERIDEX , LLC.
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS & SERVICES
10.13.3 KEY STRATEGY
10.13.4 RECENT DEVELOPMENTS
10.13.5 SWOT ANALYSIS
10.13.6 OUR COMPANY VIEW
10.14 VITATEX INC.
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS & SERVICES
10.14.3 KEY STRATEGY
10.14.4 RECENT DEVELOPMENTS
10.14.5 SWOT ANALYSIS
10.14.6 OUR COMPANY VIEW